Postmenopausal advanced breast cancer: Options for therapy after tamoxifen and aromatase inhibitors

Breast

Volumn 15, Issue 5, 2006, Pages 584-594

  Dodwell, D ^a   Wardley, A ^b   Johnston, S ^c  

^a United Kingdom   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Advanced breast cancer; Fulvestrant; Hormone receptor positive; Non steroidal AIs; Sequencing

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; DIETHYLSTILBESTROL; DROLOXIFENE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; EXEMESTANE; FORMESTANE; FULVESTRANT; GESTAGEN; IDOXIFENE; LETROZOLE; MEGESTROL ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; VOROZOLE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CROSS RESISTANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENDOMETRIUM CANCER; FEMALE; HUMAN; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOEMBOLISM; TRANSCRIPTION REGULATION; TREATMENT FAILURE;

EID: 33748573134     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2006.01.007     Document Type: Article

References (62)

1. Powles T.J., Hickish T., Kanis J.A., et al. Effect of tamoxifen on bone mineral density measured by dual-energy X- ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14 (1996) 78-84
2. Fisher B., Costantino J.P., Redmond C.K., et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86 (1994) 527-537
3. Howell S.J., Johnston S.R., and Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab 18 (2004) 47-66
4. Buzdar A., Hayes D., El-Khoudary A., et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 73 (2002) 161-175
5. Pyrhonen S., Valavaara R., Vuorinen J., and Hajba A. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 29 (1994) 223-228
6. Lønning P.E. Aromatase inhibitors in breast cancer. Endocr Relat Cancer 11 (2004) 179-189
7. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21 (2003) 2101-2109
8. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18 (2000) 3758-3767
9. The ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
10. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629
11. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18 (2000) 1399-1411
12. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 349 (2003) 1793-1802
13. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
14. Wakeling A.E., Dukes M., and Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 51 (1991) 3867-3873
15. Addo S., Yates R.A., and Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 87 (2002) 1354-1359
16. Fawell S.E., White R., Hoare S., et al. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87 (1990) 6883-6887
17. Dauvois S., White R., and Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106 Part 4 (1993) 1377-1388
18. Nicholson R.I., Gee J.M., Manning D.L., et al. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann N Y Acad Sci 761 (1995) 148-163
19. McClelland R.A., Gee J.M., Francis A.B., et al. Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. Eur J Cancer 32A (1996) 413-416
20. Pietras R.J., Marquez D.C., Chen H.W., et al. Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signalling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res Treat 82 Suppl. 1 (2003) S12 (abs 22)
21. Robertson J.F., Nicholson R.I., Bundred N.J., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61 (2001) 6739-6746
22. Inoue A., Yoshida N., Omoto Y., et al. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 29 (2002) 175-192
23. Stenbygaard L.E., Herrstedt J., Thomsen J.F., et al. Toremifene and tamoxifen in advanced breast cancer-a double-blind cross-over trial. Breast Cancer Res Treat 25 (1993) 57-63
24. Buzdar A., Jonat W., Howell A., et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 14 (1996) 2000-2011
25. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16 (1998) 453-461
26. Gershanovich M., Chaudri H.A., Campos D., et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 9 (1998) 639-645
27. Thürlimann B., Robertson J.F., Nabholtz J.M., et al. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39 (2003) 2310-2317
28. Thürlimann B., Hess D., Köberle D., et al. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 85 (2004) 247-254
29. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
30. Hu X.F., Veroni M., De Luise M., et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer 55 (1993) 873-876
31. Osborne C.K., Jarman M., McCague R., et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34 (1994) 89-95
32. Howell A., DeFriend D.J., Robertson J.F., et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 74 (1996) 300-308
33. Howell A., Robertson J.F.R., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 (2002) 3396-3403
34. Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20 (2002) 3386-3395
35. Robertson J.F., Osborne C.K., Howell A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women-a prospective combined analysis of two multicenter trials. Cancer 98 (2003) 229-238
36. Howell A., Pippen J., Elledge R.M., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104 (2005) 236-239
37. Mauriac L., Pippen J.E., Quaresma Albano J., et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 39 (2003) 1228-1233
38. Vergote I., Robertson J.F.R., Kleeberg U., et al. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 79 (2003) 207-211
39. Chan C.M., Martin L.A., Johnston S.R., et al. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 81 (2002) 333-341
40. Martin L.A., Farmer I., Johnston S.R., et al. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278 (2003) 30458-30468
41. Campos S.M. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 9 (2004) 126-136
42. Johannessen D.C., Engan T., Salle E.D., et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 3 (1997) 1101-1108
43. Lea O.A., Kvinnsland S., and Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res 49 (1989) 7162-7167
44. Bertelli G., Garrone O., and Merlano M. Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. Proc Am Soc Clin Oncol 21 (2002) 60a (abs 238)
45. Carlini P., Michelotti A., Giannarelli D., et al. Exemestane (EXE) is an effective 3rd line hormonal therapy for postmenopausal metastatic breast cancer (MBC) patients (pts) pretreated with 3rd generation non steroidal aromatase inhibitors (nSAI). Ann Oncol 13 Suppl. 5 (2002) 48
46. Fernie N.L., Zekri J.M., Leonard R.C.F., et al. Exemestane in metastatic breast cancer: effective therapy after 3rd generation aromatase inhibitor failure. Breast Cancer Res Treat 82 Suppl. 1 (2003) S104 (abs 435)
47. Lønning P.E., Bajetta E., Murray R., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18 (2000) 2234-2244
48. Thürlimann B., Paridaens R., Serin D., et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 33 (1997) 1767-1773
49. Murray R., and Pitt P. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 35 (1995) 249-253
50. Geisler J., Johannessen D.C., Anker G., and Lønning P.E. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects. Eur J Cancer 32A (1996) 789-792
51. Harper-Wynne C., and Coombes R.C. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. Eur J Cancer 35 (1999) 744-746
52. Lippman M., Bolan G., and Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36 (1976) 4595-4601
53. Masamura S., Santner S.J., Heitjan D.F., and Santen R.J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80 (1995) 2918-2925
54. Lønning P.E., Taylor P.D., Anker G., et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine treatment. Breast Cancer Res Treat 67 (2001) 111-116
55. Long B.J., Jelovac D., Thiantanawat A., and Brodie A.M. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res 8 (2002) 2378-2388
56. Perey L., Thürlimann B., Hawle H., et al. Fulvestrant ('Faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors. Breast Cancer Res Treat 76 Suppl. 1 (2002) S72 (abs 249)
57. Perey L., Paridaens R., Nolé F., et al. Fulvestrant (Faslodex™) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat 88 Suppl. 1 (2004) S236 abs 6048
58. Ingle J.N., Rowland K.M., Suman V.J., et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat 88 Suppl. 1 (2004) S38 (abs 409)
59. ®) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer: a single-center experience. Breast Cancer Res Treat 82 Suppl. 1 (2003) S105 (abs 439)
60. Petruzelka L., and Zimovjanova M. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy-results from an expanded access programme. Eur J Cancer Suppl. 2 (2004) 132 (abs 264)
61. ®) in metastatic breast cancer. Breast Cancer Res Treat 82 Suppl. 1 (2003) S104 (abs 437)
62. Cardoso A.A., Mendes G.Q., Froimtchuk M.J., et al. Fulvestrant after aromatase inhibitor failure: results from the expanded access program in Rio de Janeiro, Brazil. Breast Cancer Res Treat 88 Suppl. 1 (2004) S237